Sanofi, Regeneron report underwhelming COPD data for IL-33 antibody, shares drop
Sanofi and Regeneron on Friday reported lackluster late-stage results for their drug candidate in a common lung condition, leaving the partners to patch together a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.